Oyan, B. Et Al. 2009. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma. CLINICAL TRANSPLANTATION , vol.23, no.6 , 839-847.

Oyan, B., KOC, Y., Ozdemir, E., KARS, A., TURKER, A., TEKUZMAN, G., ... Kansu, E.(2009). High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma. CLINICAL TRANSPLANTATION , vol.23, no.6, 839-847.

Oyan, Basak Et Al. "High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma," CLINICAL TRANSPLANTATION , vol.23, no.6, 839-847, 2009

Oyan, Basak Et Al. "High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma." CLINICAL TRANSPLANTATION , vol.23, no.6, pp.839-847, 2009

Oyan, B. Et Al. (2009) . "High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma." CLINICAL TRANSPLANTATION , vol.23, no.6, pp.839-847.

@article{article, author={Basak Oyan Et Al. }, title={High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma}, journal={CLINICAL TRANSPLANTATION}, year=2009, pages={839-847} }